Audio interview of Dr. Neil Baum New Orleans Style 2015

Listen to the interview of Dr. Neil Baum share his top five places to eat and attractions you won't want to miss out on while attending the 2015 AUA annual meeting.

Related Videos

Related Content

Advertisement

May 5th 2025

AUA 2025 recap: Urologic oncology trials in progress

Hannah Clarke

Take a look through some of the notable studies that were spotlighted during this year’s meeting.

May 1st 2025

Pearls & Perspectives: Evolving role of APPs in urology, with Corinna Hughes, DNP, at AUA 2025

Amy M. Pearlman, MD

Corinna Hughes, DNP, sits down with Amy Pearlman, MD, to discuss the evolving recognition of APPs in urology.

May 2nd 2025

TAR-200 elicits high complete response rate in BCG-unresponsive NMIBC

Hannah Clarke

Data showed an overall CR rate of 82.4%.

April 30th 2025

Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025

Amy M. Pearlman, MD Ryan Terlecki, MD

A discussion on evolution of surgical education, importance of video training, and the future of patient-centered care in reconstruction.

April 30th 2025

TAR-200 boasts impressive DFS rates in papillary disease-only NMIBC

Hannah Clarke

Data showed a disease-free survival rate of 85.3% at 6 months and 81.1% at 9 months.

Published: April 29th 2025 | Updated: April 29th 2025

Ultra-low PSA responses are more prevalent with darolutamide plus ADT

Benjamin P. Saylor

The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”

Related Content

Advertisement

May 5th 2025

AUA 2025 recap: Urologic oncology trials in progress

Hannah Clarke

Take a look through some of the notable studies that were spotlighted during this year’s meeting.

May 1st 2025

Pearls & Perspectives: Evolving role of APPs in urology, with Corinna Hughes, DNP, at AUA 2025

Amy M. Pearlman, MD

Corinna Hughes, DNP, sits down with Amy Pearlman, MD, to discuss the evolving recognition of APPs in urology.

May 2nd 2025

TAR-200 elicits high complete response rate in BCG-unresponsive NMIBC

Hannah Clarke

Data showed an overall CR rate of 82.4%.

April 30th 2025

Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025

Amy M. Pearlman, MD Ryan Terlecki, MD

A discussion on evolution of surgical education, importance of video training, and the future of patient-centered care in reconstruction.

April 30th 2025

TAR-200 boasts impressive DFS rates in papillary disease-only NMIBC

Hannah Clarke

Data showed a disease-free survival rate of 85.3% at 6 months and 81.1% at 9 months.

Published: April 29th 2025 | Updated: April 29th 2025

Ultra-low PSA responses are more prevalent with darolutamide plus ADT

Benjamin P. Saylor

The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”